Clinical response to sorafenib in a patient with metastatic colorectal cancer and FLT3 amplification

Case Reports in Oncology

Volumn 8, Issue 1, 2015, Pages 83-87

  Moreira, Raphael Brandão ^a   D'Alpino Peixoto, Renata ^a   Rocha De Sousa Cruz, Marcelo ^a  

^a Centro Oncológico Antônio Ermírio de Moraes   (Brazil)

Author keywords

FLT3 amplification; Metastatic colorectal cancer; Sorafenib

Indexed keywords

BEVACIZUMAB; BILIRUBIN; CD135 ANTIGEN; DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COLONOSCOPY; DEFECATION HABIT; DNA EXTRACTION; EXON; GENE AMPLIFICATION; GENE MUTATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYBRIDIZATION; LIVER FAILURE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NEUROSURGERY; ONCOGENE; PRIORITY JOURNAL; RECTOSIGMOIDECTOMY; RECTUM CARCINOMA; SIGMOIDECTOMY; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE;

EID: 84929575728     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000375483     Document Type: Article

References (39)

1. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
2. Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, et al: A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer 2011;11:419.
3. Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, et al: Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:3279-3288.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
5. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
7. Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, Taniguchi M, et al: A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-1095.
8. Levine AJ, Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-758.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
10. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
11. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
12. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
14. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al: High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
15. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
16. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
17. Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
18. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, et al: Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet 2011;43:964-968.
19. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al: The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274.
20. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al: The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113.
21. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D: Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001;15:1001-1010.
22. Zhang S, Mantel C, Broxmeyer HE: Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol 1999;65:372-380.
23. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, et al: Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-3914.
24. Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, et al: mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer 2010;9:292.
25. The cBio Cancer Genomics Portal. 2013.
26. Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, et al: FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 2006;20:2008-2014.
27. von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, Duyster J: FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69:3032-3041.
28. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
30. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, et al: Sorafenib and radiation: A promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys 2010;78:213-220.
31. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
32. Galal KM, Khaled Z, Mourad AM: Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer 2011;48:47-54.
33. Lang L: FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008;134:379.
34. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-7278.
35. Ibrahim N, Yu Y, Walsh WR, Yang JL: Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep 2012;27:1303-1311.
36. Dal Lago L, D'Hondt V, Awada A: Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13:845-858.
37. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140.
38. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
39. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, et al: Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs 2013;31:345-354.